Showing Latest Articles
Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia
The American Journal of Cardiology, 01/20/2012
Clinical Article
Kawashiri MA et al. – Adequate introduction of this aggressive cholesterol–lowering regimen can improve the lipid profile of familial hypercholesterolemia (FH).
Methods- Authors enrolled 17 Japanese patients with heterozygous FH (12 men, 63.9 ± 7.4 years old) with single LDL receptor gene mutations in a prospective open randomized study.
- Permitted maximum doses of rosuvastatin (20 mg/day), ezetimibe (10 mg/day), and granulated colestimide (3.62 g/day) were introduced sequentially.
- Serum levels of LDL cholesterol decreased significantly by –66.4% (p <0.001) and 44% of participants achieved LDL cholesterol levels <100 mg/dl.
- There were no serious side effects or abnormal laboratory data that would have required the protocol to have been terminated except for 1 patient with myalgia.
- Coadministration of ezetimibe and granulated colestimide further lowered serum LDL cholesterol more than rosuvastatin alone without changing plasma coenzyme Q10 and proprotein convertase subtilisin/kexin type 9 levels.